Pralsetinib receives nod from EMA for use in RET-positive NSCLC
medwireNews: The EMA has recommended granting a conditional marketing authorization to pralsetinib for use in patients with RET fusion-positive non-small-cell lung cancer (NSCLC) who are RET inhibitor-naïve.
This decision by the EMA’s Committee for Medicinal Products for Human Use follows positive findings of the RET receptor tyrosine kinase inhibitor (previously known as BLU-667) in this patient population in the pivotal phase 1/2 ARROW study.
Pralsetinib will be available as 100 mg hard capsules.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group